Pulmatrix, INC. (PULM) — SEC Filings

Overview

Pulmatrix, INC. (PULM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 21, 2026: Pulmatrix, Inc. filed an 8-K on April 21, 2026, reporting under Items 7.01 (Regulation FD Disclosure) and 8.01 (Other Events). The filing includes financial statements and exhibits, with the primary document being the 8-K form itself, along with an exhibit EX-99.1. The company's mailing and business

Sentiment Summary

Across 26 filings, the sentiment breakdown is: 2 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Pulmatrix, INC. is neutral.

Filing Type Overview

Pulmatrix, INC. (PULM) has filed 1 425, 17 8-K, 1 D, 5 10-Q, 1 10-K, 1 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (26)

• Pulmatrix Files 8-K: Regulation FD & Other Events — 8-K · Apr 21, 2026 Risk: low
  Pulmatrix, Inc. filed an 8-K on April 21, 2026, reporting under Items 7.01 (Regulation FD Disclosure) and 8.01 (Other Events). The filing includes financial sta
• Pulmatrix Files Form D for Exempt Securities Offering — D · Apr 15, 2026 Risk: medium
  Pulmatrix, Inc. filed a Form D on April 15, 2026, indicating an exempt offering of securities. The company is located at 945 Concord Street, Suite 1217, Framing
• Pulmatrix Files 425 for Business Combination Communication — 425 · Mar 26, 2026
  This 425 filing from Pulmatrix, Inc. on March 26, 2026, is a communication related to a business combination. While the filing itself doesn't detail the specifi
• 8-K Filing — 8-K · Dec 18, 2025
• Pulmatrix Cash Halves Amid Merger Uncertainty, Revenue Dries Up — 10-Q · Oct 16, 2025 Risk: high
  Pulmatrix, Inc. (PULM) reported a significant decline in financial performance for the nine months ended September 30, 2025, with revenues dropping to $0 from $
• Pulmatrix Zero Revenue, Pivots to Oncology via Cullgen Merger — 10-Q · Aug 6, 2025 Risk: high
  Pulmatrix, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the thr
• Pulmatrix, Inc. Files 8-K on Shareholder Votes and Other Events — 8-K · Jun 16, 2025 Risk: low
  Pulmatrix, Inc. filed an 8-K on June 16, 2025, reporting on matters submitted to a vote of security holders and other events. The company, formerly known as Rut
• Pulmatrix, Inc. Files 8-K on Asset Acquisition/Disposition — 8-K · May 15, 2025 Risk: medium
  Pulmatrix, Inc. filed an 8-K on May 15, 2025, reporting the completion of an acquisition or disposition of assets. The filing also includes financial statements
• Pulmatrix, Inc. Reports Material Agreement & Change in Control — 8-K · Apr 10, 2025 Risk: medium
  Pulmatrix, Inc. filed an 8-K on April 10, 2025, reporting a material definitive agreement and a change in control, with the earliest event reported on April 7,
• Pulmatrix, Inc. Files 8-K on Shareholder Votes & Financials — 8-K · Apr 8, 2025 Risk: low
  Pulmatrix, Inc. filed an 8-K on April 8, 2025, reporting on matters submitted to a vote of security holders and financial statements as of April 4, 2025. The co
• Pulmatrix, Inc. Files 2024 10-K — 10-K · Mar 21, 2025 Risk: medium
  Pulmatrix, Inc. filed its 2024 10-K on March 21, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly k
• Pulmatrix, Inc. Changes Fiscal Year End — 8-K · Feb 14, 2025 Risk: low
  Pulmatrix, Inc. filed an 8-K on February 14, 2025, reporting a change in its fiscal year end to December 31st, effective February 11, 2025. This filing also inc
• Pulmatrix Files 8-K on Shareholder Vote Matters — 8-K · Dec 20, 2024 Risk: low
  Pulmatrix, Inc. filed an 8-K on December 20, 2024, reporting on matters submitted to a vote of security holders on December 18, 2024. The filing details the com
• Pulmatrix, Inc. Files 8-K: Material Agreement, Control Changes — 8-K · Nov 13, 2024 Risk: medium
  Pulmatrix, Inc. announced on November 13, 2024, that it entered into a material definitive agreement. The company also reported changes in control and updates r
• Pulmatrix, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 8, 2024 Risk: medium
  Pulmatrix, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results for the third quarter and the first nine mon
• Pulmatrix, Inc. Files 8-K on Shareholder Nominations — 8-K · Oct 8, 2024 Risk: low
  Pulmatrix, Inc. filed an 8-K on October 8, 2024, reporting shareholder nominations for its upcoming annual meeting. The filing indicates that the company receiv
• Pulmatrix, Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 13, 2024 Risk: medium
  Pulmatrix, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations.
• Pulmatrix Appoints New CMO and CFO — 8-K · Jul 19, 2024 Risk: medium
  Pulmatrix, Inc. announced on July 15, 2024, a change in its executive team. Dr. David Lee has been appointed as the new Chief Medical Officer, and Mr. Robert L.
• Pulmatrix, Inc. Files 8-K: Material Agreement and Financials — 8-K · May 29, 2024 Risk: medium
  On May 28, 2024, Pulmatrix, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported othe
• Pulmatrix, Inc. Files 8-K with Financials and Reg FD Disclosure — 8-K · May 15, 2024 Risk: low
  Pulmatrix, Inc. filed an 8-K on May 15, 2024, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibit
• Pulmatrix, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  Pulmatrix, Inc. (PULM) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Pulmatrix, Inc. filed a 10-Q report for the period ending March 31, 2024. T
• Pulmatrix, Inc. Files 8-K on Financials — 8-K · Mar 28, 2024 Risk: low
  Pulmatrix, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements an
• Pulmatrix Appoints New CMO, Elects Director — 8-K · Mar 13, 2024 Risk: medium
  Pulmatrix, Inc. announced on March 7, 2024, the appointment of Dr. David Lee as Chief Medical Officer and the election of Ms. Sarah Johnson to its Board of Dire
• Pulmatrix, Inc. Files 8-K — 8-K · Mar 4, 2024 Risk: low
  Pulmatrix, Inc. filed an 8-K on March 4, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Rut
• Pulmatrix Reports Material Agreement, Potential Financial & Officer Changes — 8-K · Jan 8, 2024
  Pulmatrix, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 6, 2024. The filing indicates significant corporate activity, inclu
• Sabby Volatility Fund Discloses 182,249 Pulmatrix Shares — SC 13G/A · Jan 2, 2024
  Sabby Volatility Warrant Master Fund, Ltd. filed an amended SC 13G/A on January 2, 2024, disclosing its beneficial ownership in Pulmatrix, Inc. as of December 3

Frequently Asked Questions